Abstract
Atrial fibrillation is the most common arrhythmia requiring
treatment interventions with a high prevalence in elderly patients. In elderly
asymptomatic patients rate control is the therapy of choice, whereas in
symptomatic patients antiarrhythmic therapy or pulmonary vein isolation would
be preferred. However, many currently used antiarrhythmic drugs have limited
efficacy and cause irreversible organ toxicity. Amiodarone is the most potent
antiarrhythmic agent for the treatment of atrial fibrillation. However, its use
is limited by toxic effects on thyroid, lungs, liver, cornea, skin, and
peripheral nerves. Thus compound development is more focused on congeners of
Amiodarone. Dronedarone is a noniodinated benzofuran with similar
electrophysiological effects compared to Amiodarone. Other compounds are under
investigation. This review summarizes preclinical and clinical findings of
these agents.
Literatur
-
1
Laughlin J C, Kowey P R.
Dronedarone: a new treatment for atrial fibrillation.
J Cardiovasc Electrophysiol.
2008;
19
1220-1226
-
2
Verma A.
Atrial-fibrillation ablation should be considered first-line
therapy for some patients.
Curr Opin Cardiol.
2008;
23
1-8
-
3
Singh B N.
Amiodarone as paradigm for developing new drugs for atrial
fibrillation.
J Cardiovasc Pharmacol.
2008;
52
300-305
-
4
Doggrell S A, Hancox J C.
Dronedarone: an amiodarone analogue.
Expert Opin Investig Drugs.
2004;
13
415-426
-
5
Christ T, Wettwer E, Voigt N. et al .
Pathology-specific effects of the IKur/Ito/IK,ACh blocker
AVE0118 on ion channels in human chronic atrial fibrillation.
Br J Pharmacol.
2008;
154
1619-1630
-
6
Schmitt J, Ehrlich J R, Hohnloser S H.
New antiarrhythmic drugs for the treatment of atrial
fibrillation.
Herz.
2008;
33
562-567
-
7
Gautier P, Serre M, Cosnier-Pucheu S. et al .
In vivo and in vitro antiarrhythmic effects of SSR149744C in
animal models of atrial fibrillation and ventricular arrhythmias.
J Cardiovasc Pharmacol.
2005;
45
125-135
-
8
Gautier P, Guillemare E, Marion A. et al .
Electrophysiologic characterization of dronedarone in guinea
pig ventricular cells.
J Cardiovasc Pharmacol.
2003;
41
191-202
-
9
Djandjighian L, Planchenault J, Finance O. et al .
Hemodynamic and antiadrenergic effects of dronedarone and
amiodarone in animals with a healed myocardial infarction.
J Cardiovasc Pharmacol.
2000;
36
376-383
-
10
Lalevée N, Nargeot J, Barrére-Lemaire S. et al .
Effects of amiodarone and dronedarone on voltage-dependent
sodium current in human cardiomyocytes.
J Cardiovasc Electrophysiol.
2003;
14
885-890
-
11
Touboul P, Brugada J, Capucci A. et al .
Dronedarone for prevention of atrial fibrillation: a
dose-ranging study.
Eur Heart J.
2003;
24
1481-1487
-
12
Singh B N, Connolly S J, Crijns H J. et al .
EURIDIS and ADONIS Investigators. N Dronedarone for
maintenance of sinus rhythm in atrial fibrillation or flutter.
Engl J Med.
2007;
357
987-999
-
13
Hohnloser S H, Crijns H J, van Eickels M. et al .
ATHENA Investigators. Effect of dronedarone on cardiovascular
events in atrial fibrillation.
N Engl J Med.
2009;
360
668-678
-
14
Davy J M, Herold M, Hoglund C. et al .
ERATO Study Investigators. Dronedarone for the control of
ventricular rate in permanent atrial fibrillation: the Efficacy and safety of
dronedarone for the control of ventricular rate during atrial fibrillation
(ERATO) study.
Am Heart J.
2008;
156
527-0
-
15
Kober L, Torp-Pedersen C, McMurray J J. et al .
Dronedarone Study Group. Increased mortality after
dronedarone therapy for severe heart failure.
N Engl J Med.
2008;
358
2678-2687
-
16
Tschuppert Y, Buclin T, Rothuizen L E. et al .
Effect of dronedarone on renal function in healthy
subjects.
Br J Clin Pharmacol.
2007;
64
785-791
-
17
Savelieva I, Camm J.
Anti-arrhythmic drug therapy for atrial fibrillation: current
anti-arrhythmic drugs, investigational agents, and innovative approaches.
Europace.
2008;
10
647-665
-
18
Kowey P R, Aliot E M, Capucci A. et al .
Placebo-controlled double-blind dose ranging study of the
efficacy and safety of SSR149744C in patients with recentatrial
fibrillation/flutter.
Heart Rhythm.
2007;
4
72 (abstract)
-
19
Arya A, Silberbauer J, Sulke N, Camm A J.
A phase 2 pilot study of the efficacy of AT-2042 in subjects
with paroxysmal atrial fibrillation and implanted pacemakers.
Heart Rhythm.
2006;
3
164
Prof. Dr. med Alexander Bauer
Abteilung Kardiologie, Angiologie und
Pneumologie
Universitätsklinikum Heidelberg
Im Neuenheimer Feld 410
69120 Heidelberg
eMail: Alexander.Bauer@med.uni-heidelberg.de
